In line with that, a study conducted on malignant mesothelioma (MM) cells proposes that combining chemotherapeutic drugs with IL-1 receptor antagonist may have a beneficial effect on MM tumor reduction [13]; specifically, treatment with cisplatin or doxorubicin induced NLRP3 inflammasome priming and activation, both an anti-tumorigenic effect (through caspase-1-dependent cell death) and pro-tumor effect (through enhanced IL-1β, IL-18, fibroblast growth factor 2 (FGF2), and HMGB1 release) ensuing. Here, NLRP3 is linked to Miyoshi myopathy.